Skip to content
★ Sign in to follow
ZG

Zhejiang Garden Biopharmaceutical Co.,Ltd. Stock: price and insider trades · China

花园生物

CN·Mcap CN¥7.1BHealth Care

No insider purchase over the last 90 days. The latest, by 邵徐君, was filed 15 Nov 2021.

Zhejiang Garden Biopharmaceutical Co.,Ltd.: what insiders have been doing

This page follows insider dealings at Zhejiang Garden Biopharmaceutical Co.,Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. No insider at Zhejiang Garden Biopharmaceutical Co.,Ltd. has published a filing in the past twelve months. The most recent one dates from 15 November 2021.

Looking back to 2021, when coverage begins, insiders filed 3 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
3
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 15 Nov 2021 · 1821 days ago · €222k
    +24.5%
    Entry CN¥13.26 · Close at T+365 CN¥16.51

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 11,509 of 26,911 companies
55.3
score / 100
Value
46
Quality
64
FCF yld1.6%
Earn yld4.3%
EV/EBITDA15.7x
ROE8.0%
Gross mgn56%
Net mgn25%
Debt/EBITDA3.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥12.98
Analyst consensus
1 analysts
·
CN¥22.00Target CN¥22.00(+69%)CN¥22.00
Income statement
RevenueCN¥1.2B
Gross profitCN¥688.3M56% margin
EBITDACN¥563.4M46% margin
Net incomeCN¥304.9M21.3% margin
Valuation
PER (trailing)28.8x
P/Book2.0x
Beta0.48
Balance sheet & cash
Market capCN¥7.1B
Total debtCN¥1.7B
Free Cash FlowCN¥112.8M
Debt / Equity51%
Profitability & ownership
ROE8.0%
ROA3.7%
% insiders32.1%
% institutions7.7%
Last declaration on 15 November 2021
Declarations3 total
  • ▲
    董事Executives
    2M CNY8SZSE
    119,600 shares9.1% of flowA股XSHESZSE:173000005272983100
    Canonical exit: 13 Feb 2022 (T+90)
  • ▲
    董事Executives
    11M CNY13SZSE
    831,000 shares63.2% of flowA股XSHESZSE:173000005272986100
    Canonical exit: 10 Feb 2022 (T+90)
  • ▲
    董事Executives
    5M CNY10SZSE
    369,200 shares27.7% of flowA股XSHESZSE:173000005710122050
    Canonical exit: 9 Feb 2022 (T+90)

3 of 3 declarations

About Zhejiang Garden Biopharmaceutical Co.,Ltd.

花园生物 is a company focused on the health and pharmaceutical sector, dedicated to developing innovative biological solutions. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations